IN2014DN10576A - - Google Patents
Info
- Publication number
- IN2014DN10576A IN2014DN10576A IN10576DEN2014A IN2014DN10576A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A IN 10576DEN2014 A IN10576DEN2014 A IN 10576DEN2014A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A
- Authority
- IN
- India
- Prior art keywords
- bruton
- inhibitors
- compositions
- useful
- same
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657360P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044800 WO2013185084A1 (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10576A true IN2014DN10576A (fa) | 2015-08-28 |
Family
ID=49712704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10576DEN2014 IN2014DN10576A (fa) | 2012-06-08 | 2013-06-07 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9394277B2 (fa) |
| EP (3) | EP3753934A1 (fa) |
| JP (6) | JP6214643B2 (fa) |
| KR (4) | KR20200043497A (fa) |
| CN (3) | CN113549055A (fa) |
| AR (1) | AR091273A1 (fa) |
| AU (5) | AU2013271407B2 (fa) |
| BR (2) | BR112014030655B1 (fa) |
| CA (2) | CA2875799C (fa) |
| CY (1) | CY1120638T1 (fa) |
| DK (1) | DK2858499T3 (fa) |
| EA (2) | EA027823B1 (fa) |
| ES (2) | ES2684268T3 (fa) |
| HR (1) | HRP20181294T1 (fa) |
| HU (1) | HUE039897T2 (fa) |
| IL (2) | IL235938B (fa) |
| IN (1) | IN2014DN10576A (fa) |
| LT (1) | LT2858499T (fa) |
| MX (2) | MX363672B (fa) |
| NZ (1) | NZ702715A (fa) |
| PH (2) | PH12018501463B1 (fa) |
| PL (1) | PL2858499T3 (fa) |
| PT (1) | PT2858499T (fa) |
| RS (1) | RS57978B1 (fa) |
| SG (2) | SG11201408173WA (fa) |
| SI (1) | SI2858499T1 (fa) |
| SM (1) | SMT201800442T1 (fa) |
| TW (3) | TWI592406B (fa) |
| WO (1) | WO2013185084A1 (fa) |
| ZA (1) | ZA201409255B (fa) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI711610B (zh) * | 2009-09-04 | 2020-12-01 | 美商百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| JP6431914B2 (ja) * | 2013-12-11 | 2018-11-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| LT3461821T (lt) | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
| US11174243B2 (en) * | 2016-07-21 | 2021-11-16 | Sunesis Pharmaceuticals, Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
| JP7331843B2 (ja) | 2018-04-27 | 2023-08-23 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN117281803A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
| CA3241069A1 (en) | 2021-12-14 | 2023-06-22 | Adrianus Petrus Antonius De Man | Macrocyclic btk inhibitors |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1624A (en) * | 1840-06-10 | Cooking-stove | ||
| US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| WO2001070673A2 (en) | 2000-03-17 | 2001-09-27 | Bristol-Myers Squibb Pharma Company | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| AP1911A (en) | 2000-06-26 | 2008-10-30 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds. |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| MXPA04004019A (es) | 2001-10-31 | 2004-07-08 | Bayer Healthcare Ag | Derivados de pirimido?4,5-b?indol. |
| GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| WO2006073419A2 (en) * | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| JP5030229B2 (ja) * | 2004-11-04 | 2012-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−ａ］ピリミジン |
| AU2005311930B9 (en) | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
| WO2006071819A1 (en) | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| US20090325948A1 (en) | 2006-07-26 | 2009-12-31 | Timothy Brian Hurley | Inhibitors of undecaprenyl pyrophosphate synthase |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| JP2010502751A (ja) * | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| SI2529622T1 (en) | 2006-09-22 | 2018-06-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
| EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| RU2469036C2 (ru) | 2007-06-01 | 2012-12-10 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Имидазопиридиновые ингибиторы киназ |
| EP2242749B1 (en) * | 2008-02-05 | 2013-04-10 | F. Hoffmann-La Roche AG | Novel pyridinones and pyridazinones |
| ES2542066T3 (es) | 2008-04-29 | 2015-07-30 | Immunexcite, Inc. | Composiciones inmunomoduladoras y métodos de uso de las mismas |
| WO2010009342A2 (en) | 2008-07-16 | 2010-01-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| PE20110819A1 (es) * | 2008-12-19 | 2011-11-02 | Bristol Myers Squibb Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa |
| CA2748181C (en) * | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| ES2565952T3 (es) | 2009-05-25 | 2016-04-07 | Sandoz Ag | Método para la producción de ceftobiprol medocaril |
| TWI711610B (zh) | 2009-09-04 | 2020-12-01 | 美商百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| US8685880B2 (en) * | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| JP6431914B2 (ja) | 2013-12-11 | 2018-11-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| WO2016054627A1 (en) | 2014-10-03 | 2016-04-07 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
| US11174243B2 (en) * | 2016-07-21 | 2021-11-16 | Sunesis Pharmaceuticals, Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko not_active Ceased
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en not_active IP Right Cessation
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en not_active Ceased
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh not_active Expired - Fee Related
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja not_active Expired - Fee Related
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en not_active Withdrawn
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en not_active Ceased
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt not_active IP Right Cessation
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko not_active Expired - Fee Related
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh not_active IP Right Cessation
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh not_active IP Right Cessation
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en not_active Not-in-force
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh not_active IP Right Cessation
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active Active
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Ceased
- 2013-06-07 MX MX2019003618A patent/MX385593B/es unknown
- 2013-06-07 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 PH PH1/2018/501463A patent/PH12018501463B1/en unknown
- 2013-06-08 SM SM20180442T patent/SMT201800442T1/it unknown
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699A1/en unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en not_active Ceased
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en not_active Ceased
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en not_active Abandoned
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en not_active Abandoned
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
-
2024
- 2024-08-23 US US18/813,750 patent/US20240417389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10576A (fa) | ||
| MY179781A (en) | Biaryl inhibitors of bruton's tyrosine kinase | |
| IN2015DN00127A (fa) | ||
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MX356753B (es) | Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| IN2014DN09346A (fa) | ||
| MY160734A (en) | Besylate salt of a btk inhibitor | |
| WO2013185082A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2015015421A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2015015417A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
| IL259863B (en) | Polycyclic compounds as inhibitors of proton tyrosine kinase | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| WO2012122383A3 (en) | Pi3 kinase inhibitors and uses thereof | |
| EA201590268A1 (ru) | Ариллактамные ингибиторы киназы | |
| EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX2019000884A (es) | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. | |
| NZ743260A (en) | Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors | |
| NZ737572A (en) | Intermediate compounds for the preparation of bipiperidine-2-one compounds |